Concord Biosciences LLC
http://www.ricerca.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Concord Biosciences LLC
Cempra's $50M from shrunken IPO leaves development gaps in antibiotic programme
The US antibiotics developer Cempra Inc, founded in 2006, has successfully gone public, but with a reduced offering. The Chapel Hill, North Carolina-based company raised $50.4 million with expected net proceeds of $46.7 million. But that fell well short of the $70-plus the company was looking for just two weeks ago, meaning that it will still need to raise more cash to complete development of its two lead candidate antibiotics.
Trends in Big Pharma Out-Licensing
In Vivo ranks Big Pharmas by levels of out-licensing over the past five years.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Frontage Laboratories, Inc. Ricerca Biosciences
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice